NEWS
cbdMD Announces Publication of Human Clinical Trial Data
cbdMD (NYSE: YCBD) announced the publication of its human clinical trial data in the Journal of the International Society of Sports Nutrition. The study, conducted by the University of South Carolina, evaluated the effects of daily intake of 100 mg of cbdMD's Broad Spectrum CBD blend over 12 weeks on healthy adults.
Key findings include significant pain reduction, improved psychological well-being in male participants, and reduced perceived stress in female participants. The study confirmed the safety and tolerability of the product, aligning with previous research on safe CBD consumption levels.
cbdMD highlighted the trial as evidence of their commitment to science, safety, and efficacy, reinforcing their leadership in the CBD industry.
Key findings include significant pain reduction, improved psychological well-being in male participants, and reduced perceived stress in female participants. The study confirmed the safety and tolerability of the product, aligning with previous research on safe CBD consumption levels.
cbdMD highlighted the trial as evidence of their commitment to science, safety, and efficacy, reinforcing their leadership in the CBD industry.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment